NFXBio: Why C2i is the World’s First Platform for Cancer Intelligence

In this episode, James Currier and Omri Amirav-Drory delve into synthetic biology and tech bio, introducing guest Asaf Zviran, CEO of C2I. They discuss the impact of tech bio on industries, strategies for hiring and fundraising in a virtual world, and the balance between science and business in startups. They also explore the future of cancer treatment and provide valuable advice for startup founders.

Episode metadata supplied by the publisher feed · Published Jun 25, 2021

Embed this episode

Attribution link and audio player

NOW PLAYING

NFXBio: Why C2i is the World’s First Platform for Cancer Intelligence

0:00 48:54

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The NFX Podcast?

This episode is 48 minutes long.

When was this The NFX Podcast episode published?

This episode was published on June 25, 2021.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this The NFX Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!